Alzheimer disease is a progressive neurodegenerative disorder that impairs memory and mental function. It is the most common form of dementia, accounting for 60–70% of cases, and its prevalence is ...
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...
The July approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) marks the third HDAC inhibitor to gain registration in the US and the first in almost five years—all for treating ...
DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...
Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...
As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...
Preclinical studies suggest that blocking histone deacetylases, which modulate gene transcription, could potentially treat neurodegeneration, but in practice, the theory has not lived up to its ...
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation that is greater in patients with advanced disease. We asked whether there is a link between the severity of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results